ArticleJournal of clinical medicine2020
In Vivo Quantification of Myocardial Amyloid Deposits in Patients with Suspected Transthyretin-Related Amyloidosis (ATTR).
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis.BMC cardiovascular disorders · 2021Pooled it
- Cardiac amyloidosis: From diagnosis to therapeutics breakthroughs.World journal of experimental medicine · 2026Review
- Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis.European heart journal. Cardiovascular Imaging · 2025Article
- 2025 Update Consensus ofActa Cardiologica Sinica · 2025Article
- Single-center analysis of cardiac amyloidosis using 99m Tc-HMDP imaging for diagnosis and evaluation after tafamidis treatment.Nuclear medicine communications · 2025Article
- DPD Quantification Correlates With Extracellular Volume and Disease Severity in Wild-Type Transthyretin Cardiac Amyloidosis.JACC. Advances · 2024Article
- Cardiac DPD-uptake time dependency in ATTR patients verified by quantitative SPECT/CT and semiquantitative planar parameters.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.European heart journal. Cardiovascular Imaging · 2023Article
- Quantitative SPECT/CT Parameters in the Assessment of Transthyretin Cardiac Amyloidosis-A New Dimension of Molecular Imaging.Journal of cardiovascular development and disease · 2023Review
- Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Review
- Quantitative myocardial perfusion SPECT/CT for the assessment of myocardial tracer uptake in patients with three-vessel coronary artery disease: Initial experiences and results.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Nuclear Molecular Imaging of Disease Burden and Response to Treatment for Cardiac Amyloidosis.Biology · 2022Review
- Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent diagnosis of Transthyretin-related Amyloidosis (ATTR) using bone scintigraphy is primarily based on visual scoring and semi-quantitative indices. With the introduction of new potential life-prolonging drugs for ATTR, a more precise quantification of myocardial amyloid burden is desirable for improved response prediction and therapy monitoring.
methodsAt first, quantification experiments using an anthropomorphic thorax phantom were performed. Second, 32 patients underwent both planar whole body [
resultsPhantom measurements showed a strong linear relationship between the activity in the myocardial insert and the measured activity (r = 0.9998,
conclusionSUV quantification of ATTR amyloid burden is feasible using novel SPECT/CT technology. With a SUVpeak cut-off of 3.1, patients with Perugini grade 2 and 3 could be clearly separated from those with Perugini grade 0 and 1. Besides ATTR diagnostics, quantification of amyloid deposits could potentially be used for therapy monitoring and prognostication in patients with cardiac ATTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.